Tharimmune (THAR)

• Market cap: $85.9M
• 1 day: 8.89%
• 5 days: -14.63%
• 1 month: -18.06%
• 3 months: -50.7%
• 6 months: 81.48%
• Year to date: 19.51%
• 1 year: -6.13%
• 5 years: -99.81%
• 10 years: -99.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Employees: 3